​

Beam Therapeutics Ownership | Who Owns Beam Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Beam Therapeutics Ownership Summary

Beam Therapeutics is owned by 16.97% institutional investors, 1.23% insiders, and 81.80% retail investors. Ark investment management is the largest institutional shareholder, holding 12.15% of BEAM shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 8.57% of its assets in Beam Therapeutics shares.

BEAM Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBeam Therapeutics16.97%1.23%81.80%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management12.47M12.15%$345.59M
Fmr11.69M11.46%$283.79M
Farallon capital management10.06M9.87%$244.23M
Blackrock7.63M9.34%$178.87M
Vanguard group9.19M8.96%$254.84M
Blackrock funding, inc. /de8.45M8.24%$234.24M
Arch venture management4.54M4.45%$110.19M
Nikko asset management americas4.41M4.30%$122.18M
Sumitomo mitsui trust4.41M4.30%$122.23M
State street4.01M3.93%$97.29M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mwg management2.27M67.66%$55.02M
Arch venture management4.54M22.38%$110.19M
Kynam capital management, lp2.52M4.55%$61.10M
Peregrine investment management257.28K4.43%$7.13M
Redmile group1.39M3.28%$33.68M
Casdin capital1.60M3.24%$38.83M
Ark investment management12.47M2.29%$345.59M
Bellevue group2.89M1.46%$70.12M
Nikko asset management americas4.41M1.41%$122.18M
Iq eq fund management (ireland)533.56K1.02%$14.79M

Top Buyers

HolderShares% AssetsChange
Ark investment management12.47M2.29%1.43M
Blackrock7.63M0.00%928.75K
Bnp paribas arbitrage, snc468.91K0.01%444.94K
State street4.01M0.00%370.39K
Blackrock funding, inc. /de8.45M0.00%301.98K

Top Sellers

HolderShares% AssetsChange
Darwin global management---2.12M
Temasek (private)---1.81M
Contrarius group---1.53M
Fmr11.69M0.01%-1.27M
Deerfield management company, l.p. (series c)---877.81K

New Positions

HolderShares% AssetsChangeValue
Adage capital partners gp175.00K0.01%175.00K$4.25M
Renaissance156.50K0.01%156.50K$4.34M
Jump financial144.50K0.04%144.50K$3.51M
Readystate asset management lp93.93K0.10%93.93K$2.28M
Ameriprise financial88.73K0.00%88.73K$2.15B

Sold Out

HolderChange
Global financial private client-4.00
Southstate-5.00
Massmutual trust co fsb/adv-5.00
Ameritas advisory services-6.00
Assetmark-8.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202575-67.39%17,407,248-83.67%160.16%41-67.20%20-61.54%
Sep 30, 202580-63.96%18,739,586-81.85%180.18%38-66.37%19-70.31%
Jun 30, 2025229-4.98%108,356,4618.36%1060.82%117-17.61%6544.44%
Mar 31, 20252421.26%101,365,37024.41%1151.18%14316.26%46-28.13%
Dec 31, 20242373.95%81,473,3153.08%981.07%12017.65%65-1.52%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite8.73M8.57%828.82K
ARK Innovation ETF8.70M8.54%118.14K
Fidelity Growth Compy Commingled Pl S4.31M4.23%46.51K
Fidelity Growth Company Fund3.19M3.13%15.52K
State Street® SPDR® S&P® Biotech ETF3.05M2.99%-16.32K
Nikko AM ARK Disruptive Innovation A USD2.92M2.90%-98.23K
Amova ARK Disruptive Innovation A USD2.95M2.90%-66.25K
BB Biotech AG Ord2.89M2.84%-
Vanguard Total Stock Mkt Idx Inv2.89M2.83%9.16K
Vanguard US Total Market Shares ETF2.33M2.34%2.59K

Recent Insider Transactions

DateNameRoleActivityValue
Feb 24, 2026Ciaramella Giuseppe PresidentSell$1.12M
Jan 29, 2026Evans John M. CEOSell$476.80K
Jan 29, 2026Evans John M. CEOSell$257.78K
Jan 30, 2026Evans John M. CEOSell$624.67K
Jan 30, 2026Evans John M. CEOSell$84.27K

Insider Transactions Trends

DateBuySell
2033 Q2--
2024 Q4-2
2024 Q3-3
2024 Q2-7
2024 Q1-7

BEAM Ownership FAQ

Who Owns Beam Therapeutics?

Beam Therapeutics shareholders are primarily institutional investors at 16.97%, followed by 1.23% insiders and 81.80% retail investors. The average institutional ownership in Beam Therapeutics's industry, Biotech Stocks , is 381.47%, which Beam Therapeutics falls below.

Who owns the most shares of Beam Therapeutics?

Beam Therapeutics’s largest shareholders are Ark investment management (12.47M shares, 12.15%), Fmr (11.69M shares, 11.46%), and Farallon capital management (10.06M shares, 9.87%). Together, they hold 33.49% of Beam Therapeutics’s total shares outstanding.

Does Blackrock own Beam Therapeutics?

Yes, BlackRock owns 9.34% of Beam Therapeutics, totaling 7.63M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 178.87M$. In the last quarter, BlackRock increased its holdings by 928.75K shares, a 13.85% change.

Who is Beam Therapeutics’s biggest shareholder by percentage of total assets invested?

Mwg management is Beam Therapeutics’s biggest shareholder by percentage of total assets invested, with 67.66% of its assets in 2.27M Beam Therapeutics shares, valued at 55.02M$.

Who is the top mutual fund holder of Beam Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Beam Therapeutics shares, with 8.57% of its total shares outstanding invested in 8.73M Beam Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools